GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (FRA:42Z) » Definitions » Short Percentage of Float

Revolution Medicines (FRA:42Z) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Revolution Medicines's Short Percentage of Float

For the Biotechnology subindustry, Revolution Medicines's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revolution Medicines's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's Short Percentage of Float falls into.


Revolution Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (FRA:42Z) » Definitions » Short Percentage of Float
Comparable Companies
ASND ROIV JAZZ MDGL EXEL PCVX HALO LEGN NUVL BPMC VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
RVMD:USA
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Website
https://www.revmed.com
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines Headlines

No Headlines